Oncology

Pharmaceutical company announces Phase I clinical trial for myeloma treatment

Published in Health and Medicine Week, December 6th, 2004

Kosan Biosciences announced that it has initiated a company-sponsored Phase Ib clinical trial to investigate KOS-953, Kosan's formulation of 17-AAG in combination with bortezomib (Velcade), a recently approved agent to treat relapsed/refractory myeloma.

The Phase Ib clinical trial will evaluate the safety of the combination and determine an appropriate dose and schedule for the use of KOS-953 in combination with Velcade. Dr. Asher Chanan-Khan, principal investigator at Roswell Park Cancer Center, was the first site to begin enrollment; additional centers will include Dana Farber Cancer Center, H. Lee Moffitt Cancer Center and Arizona Cancer Center.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2004-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry